Skip to main content
Top
Published in: Inflammation 5/2020

01-10-2020 | Acute Respiratory Distress-Syndrome | Original Article

Curcumin Promotes the Expression of IL-35 by Regulating Regulatory T Cell Differentiation and Restrains Uncontrolled Inflammation and Lung Injury in Mice

Authors: Yan-qing Chen, Yu-sen Chai, Ke Xie, Feng Yu, Chuan-jiang Wang, Shi-hui Lin, Yuan-zheng Yang, Fang Xu

Published in: Inflammation | Issue 5/2020

Login to get access

Abstract

Interleukin (IL)-35, which has an anti-inflammatory role in acute respiratory distress syndrome (ARDS)/acute lung injury (ALI), is relatively promising as a drug target. Studies have shown that curcumin may play a therapeutic role in ALI and enhance the suppressive function of regulatory T cells (Tregs). To illustrate the effect of curcumin on the regulation of Treg cell differentiation and expression of IL-35, we built a cecal ligation and puncture (CLP)–induced acute lung injury mouse mode with curcumin pretreatment. The expression of IL-35 in serum, severity of lung injury, IL-17A in lung tissue, survival rate, Treg-related cytokines levels in serum, nuclear factor-kappa B (NF-κB)’s nuclear translocation in lung tissue, and splenic CD4+CD25+FOXP3+ Tregs were assessed. Furthermore, the proportion of Tregs, STAT5, and IL-35 expression during naïve CD4+ T cell differentiation in vitro was measured. Compared with the CLP group, the increased IL-35 expression in CLP with the curcumin pretreatment (CLP + Cur) group was consistent with the decreased severity of lung injury, IL-17A protein levels in lung tissue, and Treg-related cytokines levels. Pretreatment with curcumin, the survival rate climbed to 50%, while the mortality rate was 100% in the CLP group. In addition, splenic CD4+CD25+FOXP3+ Treg cells increased in the CLP + Cur group. In vitro, CD4+CD25+FOXP3+ Treg cells from naïve CD4+ T cells, STAT5 proportion, and IL-35 expression increased after curcumin treatment. These findings showed that curcumin might regulate IL-35 by activating the differentiation of Treg cells to control the inflammation in acute lung injury.
Literature
1.
go back to reference Bellani, G., J.G. Laffey, T. Pham, E. Fan, L. Brochard, A. Esteban, L. Gattinoni, F. van Haren, A. Larsson, D. McAuley, M. Ranieri, G. Rubenfeld, B.T. Thompson, H. Wrigge, A.S. Slutsky, A. Pesenti, LUNG SAFE Investigators, and ESICM Trials Group. 2016. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. Jama 315: 788–800.CrossRef Bellani, G., J.G. Laffey, T. Pham, E. Fan, L. Brochard, A. Esteban, L. Gattinoni, F. van Haren, A. Larsson, D. McAuley, M. Ranieri, G. Rubenfeld, B.T. Thompson, H. Wrigge, A.S. Slutsky, A. Pesenti, LUNG SAFE Investigators, and ESICM Trials Group. 2016. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. Jama 315: 788–800.CrossRef
2.
go back to reference Restrepo, M.I., J.D. Chalmers, Y. Song, C. Mallow, J. Hewlett, F. Maldonado, et al. 2017. Year in review 2016: respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology. Respirology (Carlton, Vic) 22: 602–611.CrossRef Restrepo, M.I., J.D. Chalmers, Y. Song, C. Mallow, J. Hewlett, F. Maldonado, et al. 2017. Year in review 2016: respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology. Respirology (Carlton, Vic) 22: 602–611.CrossRef
3.
go back to reference Blondonnet, R., J.M. Constantin, V. Sapin, and M. Jabaudon. 2016. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Disease Markers 2016: 3501373.CrossRef Blondonnet, R., J.M. Constantin, V. Sapin, and M. Jabaudon. 2016. A pathophysiologic approach to biomarkers in acute respiratory distress syndrome. Disease Markers 2016: 3501373.CrossRef
4.
go back to reference Collison, L.W., C.J. Workman, T.T. Kuo, K. Boyd, Y. Wang, K.M. Vignali, R. Cross, D. Sehy, R.S. Blumberg, and D.A.A. Vignali. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566–569.CrossRef Collison, L.W., C.J. Workman, T.T. Kuo, K. Boyd, Y. Wang, K.M. Vignali, R. Cross, D. Sehy, R.S. Blumberg, and D.A.A. Vignali. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566–569.CrossRef
5.
go back to reference Wang, C.J., M. Zhang, H. Wu, S.H. Lin, and F. Xu. 2019. IL-35 interferes with splenic T cells in a clinical and experimental model of acute respiratory distress syndrome. International Immunopharmacology 67: 386–395.CrossRef Wang, C.J., M. Zhang, H. Wu, S.H. Lin, and F. Xu. 2019. IL-35 interferes with splenic T cells in a clinical and experimental model of acute respiratory distress syndrome. International Immunopharmacology 67: 386–395.CrossRef
6.
go back to reference Cao, J., F. Xu, S. Lin, X. Tao, Y. Xiang, X. Lai, et al. 2015. IL-35 is elevated in clinical and experimental sepsis and mediates inflammation. Clinical immunology (Orlando, Fla) 161: 89–95.CrossRef Cao, J., F. Xu, S. Lin, X. Tao, Y. Xiang, X. Lai, et al. 2015. IL-35 is elevated in clinical and experimental sepsis and mediates inflammation. Clinical immunology (Orlando, Fla) 161: 89–95.CrossRef
7.
go back to reference Lelli, D., A. Sahebkar, T.P. Johnston, and C. Pedone. 2017. Curcumin use in pulmonary diseases: state of the art and future perspectives. Pharmacological Research 115: 133–148.CrossRef Lelli, D., A. Sahebkar, T.P. Johnston, and C. Pedone. 2017. Curcumin use in pulmonary diseases: state of the art and future perspectives. Pharmacological Research 115: 133–148.CrossRef
8.
go back to reference Xu, F., S.H. Lin, Y.Z. Yang, R. Guo, J. Cao, and Q. Liu. 2013. The effect of curcumin on sepsis-induced acute lung injury in a rat model through the inhibition of the TGF-beta1/SMAD3 pathway. International Immunopharmacology 16: 1–6.CrossRef Xu, F., S.H. Lin, Y.Z. Yang, R. Guo, J. Cao, and Q. Liu. 2013. The effect of curcumin on sepsis-induced acute lung injury in a rat model through the inhibition of the TGF-beta1/SMAD3 pathway. International Immunopharmacology 16: 1–6.CrossRef
9.
go back to reference Chen, L., Y. Lu, L. Zhao, L. Hu, Q. Qiu, Z. Zhang, M. Li, G. Hong, B. Wu, G. Zhao, and Z. Lu. 2018. Curcumin attenuates sepsis-induced acute organ dysfunction by preventing inflammation and enhancing the suppressive function of Tregs. International Immunopharmacology 61: 1–7.CrossRef Chen, L., Y. Lu, L. Zhao, L. Hu, Q. Qiu, Z. Zhang, M. Li, G. Hong, B. Wu, G. Zhao, and Z. Lu. 2018. Curcumin attenuates sepsis-induced acute organ dysfunction by preventing inflammation and enhancing the suppressive function of Tregs. International Immunopharmacology 61: 1–7.CrossRef
10.
go back to reference Gouda, M.M., and Y.P. Bhandary. 2019. Acute lung injury: IL-17A-mediated inflammatory pathway and its regulation by curcumin. Inflammation 42: 1160–1169.CrossRef Gouda, M.M., and Y.P. Bhandary. 2019. Acute lung injury: IL-17A-mediated inflammatory pathway and its regulation by curcumin. Inflammation 42: 1160–1169.CrossRef
11.
go back to reference Omenetti, S., and T.T. Pizarro. 2015. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Frontiers in Immunology 6: 639.CrossRef Omenetti, S., and T.T. Pizarro. 2015. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Frontiers in Immunology 6: 639.CrossRef
12.
go back to reference Gao, S., W. Zhang, Q. Zhao, J. Zhou, Y. Wu, Y. Liu, Z. Yuan, and L. Wang. 2019. Curcumin ameliorates atherosclerosis in apolipoprotein E deficient asthmatic mice by regulating the balance of Th2/Treg cells. Phytomedicine : international journal of phytotherapy and phytopharmacology 52: 129–135.CrossRef Gao, S., W. Zhang, Q. Zhao, J. Zhou, Y. Wu, Y. Liu, Z. Yuan, and L. Wang. 2019. Curcumin ameliorates atherosclerosis in apolipoprotein E deficient asthmatic mice by regulating the balance of Th2/Treg cells. Phytomedicine : international journal of phytotherapy and phytopharmacology 52: 129–135.CrossRef
13.
go back to reference Flaherty S, Reynolds JM. Mouse naive CD4+ T cell isolation and in vitro differentiation into T cell subsets. Journal of visualized experiments : JoVE 2015. Flaherty S, Reynolds JM. Mouse naive CD4+ T cell isolation and in vitro differentiation into T cell subsets. Journal of visualized experiments : JoVE 2015.
14.
go back to reference Kim EJ, Lee JG, Kim JY, Song SH, Joo DJ, Huh, KH, et al. Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets. 2017; 152:628–637. Kim EJ, Lee JG, Kim JY, Song SH, Joo DJ, Huh, KH, et al. Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets. 2017; 152:628–637.
15.
go back to reference Ashbaugh, D.G., D.B. Bigelow, T.L. Petty, and B.E. Levine. 1967. Acute respiratory distress in adults. Lancet (London, England) 2: 319–323.CrossRef Ashbaugh, D.G., D.B. Bigelow, T.L. Petty, and B.E. Levine. 1967. Acute respiratory distress in adults. Lancet (London, England) 2: 319–323.CrossRef
16.
go back to reference Ranieri, V.M., G.D. Rubenfeld, B.T. Thompson, N.D. Ferguson, E. Caldwell, E. Fan, et al. 2012. Acute respiratory distress syndrome: the Berlin definition. Jama 307: 2526–2533.PubMed Ranieri, V.M., G.D. Rubenfeld, B.T. Thompson, N.D. Ferguson, E. Caldwell, E. Fan, et al. 2012. Acute respiratory distress syndrome: the Berlin definition. Jama 307: 2526–2533.PubMed
17.
go back to reference Calfee, C.S., K. Delucchi, P.E. Parsons, B.T. Thompson, L.B. Ware, and M.A. Matthay. 2014. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. The Lancet Respiratory Medicine 2: 611–620.CrossRef Calfee, C.S., K. Delucchi, P.E. Parsons, B.T. Thompson, L.B. Ware, and M.A. Matthay. 2014. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. The Lancet Respiratory Medicine 2: 611–620.CrossRef
18.
go back to reference Su, L.C., X.Y. Liu, A.F. Huang, and W.D. Xu. 2018. Emerging role of IL-35 in inflammatory autoimmune diseases. Autoimmunity Reviews 17: 665–673.CrossRef Su, L.C., X.Y. Liu, A.F. Huang, and W.D. Xu. 2018. Emerging role of IL-35 in inflammatory autoimmune diseases. Autoimmunity Reviews 17: 665–673.CrossRef
19.
go back to reference Teymouri M, Pirro M. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. 2018; 143:2105–2115. Teymouri M, Pirro M. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. 2018; 143:2105–2115.
20.
go back to reference Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of immunology (Baltimore, Md : 1950) 2002; 169:2756–61. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of immunology (Baltimore, Md : 1950) 2002; 169:2756–61.
21.
go back to reference Xue, W., D. Yan, and Q. Kan. 2019. Interleukin-35 as an emerging player in tumor microenvironment. Journal of Cancer 10: 2074–2082.CrossRef Xue, W., D. Yan, and Q. Kan. 2019. Interleukin-35 as an emerging player in tumor microenvironment. Journal of Cancer 10: 2074–2082.CrossRef
22.
go back to reference Lin, S., H. Wu, C. Wang, Z. Xiao, and F. Xu. 2018. Regulatory T cells and acute lung injury: cytokines, uncontrolled inflammation, and therapeutic implications. Frontiers in Immunology 9: 1545.CrossRef Lin, S., H. Wu, C. Wang, Z. Xiao, and F. Xu. 2018. Regulatory T cells and acute lung injury: cytokines, uncontrolled inflammation, and therapeutic implications. Frontiers in Immunology 9: 1545.CrossRef
23.
go back to reference D’Alessio, F.R., J.T. Kurzhagen, and H. Rabb. 2019. Reparative T lymphocytes in organ injury. The Journal of Clinical Investigation 129: 2608–2618.CrossRef D’Alessio, F.R., J.T. Kurzhagen, and H. Rabb. 2019. Reparative T lymphocytes in organ injury. The Journal of Clinical Investigation 129: 2608–2618.CrossRef
24.
go back to reference Kim, J., S.W. Jeong, H. Quan, C.W. Jeong, J.I. Choi, and H.B. Bae. 2016. Effect of curcumin (Curcuma longa extract) on LPS-induced acute lung injury is mediated by the activation of AMPK. Journal of Anesthesia 30: 100–108.CrossRef Kim, J., S.W. Jeong, H. Quan, C.W. Jeong, J.I. Choi, and H.B. Bae. 2016. Effect of curcumin (Curcuma longa extract) on LPS-induced acute lung injury is mediated by the activation of AMPK. Journal of Anesthesia 30: 100–108.CrossRef
25.
go back to reference Sakurai, R., P. Villarreal, S. Husain, J. Liu, T. Sakurai, E. Tou, J.S. Torday, and V.K. Rehan. 2013. Curcumin protects the developing lung against long-term hyperoxic injury. American Journal of Physiology Lung Cellular and Molecular Physiology 305: L301–L311.CrossRef Sakurai, R., P. Villarreal, S. Husain, J. Liu, T. Sakurai, E. Tou, J.S. Torday, and V.K. Rehan. 2013. Curcumin protects the developing lung against long-term hyperoxic injury. American Journal of Physiology Lung Cellular and Molecular Physiology 305: L301–L311.CrossRef
26.
go back to reference Liu, K., H.L. Chen, H. Huang, H. Jing, G.H. Dong, H.W. Wu, and Q.S. You. 2012. Curcumin attenuates cardiopulmonary bypass-induced lung oxidative damage in rats. Journal of Cardiovascular Pharmacology and Therapeutics 17: 395–402.CrossRef Liu, K., H.L. Chen, H. Huang, H. Jing, G.H. Dong, H.W. Wu, and Q.S. You. 2012. Curcumin attenuates cardiopulmonary bypass-induced lung oxidative damage in rats. Journal of Cardiovascular Pharmacology and Therapeutics 17: 395–402.CrossRef
27.
go back to reference Tyagi, N., D.K. Singh, D. Dash, and R. Singh. 2019. Curcumin modulates paraquat-induced epithelial to mesenchymal transition by regulating transforming growth factor-beta (TGF-beta) in A549 cells. Inflammation 42: 1441–1455.CrossRef Tyagi, N., D.K. Singh, D. Dash, and R. Singh. 2019. Curcumin modulates paraquat-induced epithelial to mesenchymal transition by regulating transforming growth factor-beta (TGF-beta) in A549 cells. Inflammation 42: 1441–1455.CrossRef
28.
go back to reference Kochetkova, I., S. Golden, K. Holderness, G. Callis, and D.W. Pascual. 2010. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. Journal of immunology (Baltimore, Md : 1950) 184: 7144–7153.CrossRef Kochetkova, I., S. Golden, K. Holderness, G. Callis, and D.W. Pascual. 2010. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. Journal of immunology (Baltimore, Md : 1950) 184: 7144–7153.CrossRef
29.
go back to reference Niedbala, W., X.Q. Wei, B. Cai, A.J. Hueber, B.P. Leung, I.B. McInnes, et al. 2007. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. European Journal of Immunology 37: 3021–3029.CrossRef Niedbala, W., X.Q. Wei, B. Cai, A.J. Hueber, B.P. Leung, I.B. McInnes, et al. 2007. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. European Journal of Immunology 37: 3021–3029.CrossRef
Metadata
Title
Curcumin Promotes the Expression of IL-35 by Regulating Regulatory T Cell Differentiation and Restrains Uncontrolled Inflammation and Lung Injury in Mice
Authors
Yan-qing Chen
Yu-sen Chai
Ke Xie
Feng Yu
Chuan-jiang Wang
Shi-hui Lin
Yuan-zheng Yang
Fang Xu
Publication date
01-10-2020
Publisher
Springer US
Published in
Inflammation / Issue 5/2020
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-020-01265-2

Other articles of this Issue 5/2020

Inflammation 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.